The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation

被引：10

作者：

Daneshmand, Siamak ^{[3
]}

Stephenson, Andrew J. ^{[4
]}

Sheinfeld, Joel ^{[5
]}

Jewett, Michael A. S. ^{[1
,2
]}

机构：

[1] Univ Toronto, Div Urol, Dept Surg & Surg Oncol, Princess Margaret Hosp, Toronto, ON M5T 3M4, Canada

[2] Univ Toronto, Univ Hlth Network, Toronto, ON M5T 3M4, Canada

[3] Univ So Calif, USC Inst Urol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA

[4] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44195 USA

[5] Mem Sloan Kettering Canc Ctr, Dept Urol Surg, New York, NY 10065 USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2011年 / 29卷 / 06期

关键词：

Testis cancer; Post-chemotherapy retroperitoneal lymph node dissection; GERM-CELL TUMORS; LYMPH-NODE DISSECTION; NONSEMINOMATOUS TESTICULAR CANCER; POSTCHEMOTHERAPY RETROPERITONEAL SURGERY; TERM-FOLLOW-UP; COMBINATION CHEMOTHERAPY; STAGE-I; PROGNOSTIC-FACTORS; SALVAGE THERAPY; LATE RELAPSE;

D O I：

10.1016/j.urolonc.2011.05.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with advanced non-seminomatous germ cell tumors may achieve a serologic and radiographic complete response (CR) to first-line chemotherapy (defined as a residual mass < 1 cm in size). Recent reports suggest that these patients may be observed with a low rate of relapse but there remain compelling arguments for surgical excision. The arguments for and against post-chemotherapy retroperitoneal lymph node dissection (pcRPLND) are presented. There is clear consensus that patient's with residual masses > 1 cm should undergo post-chemotherapy surgery. (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：842 / 847

页数：6

共 50 条

[1] Management of the post chemotherapy subcentimeter residual mass: the case for observation
Stephen D. W. Beck
Richard S. Foster
World Journal of Urology, 2009, 27 : 485 - 488
[2] Management of the post chemotherapy subcentimeter residual mass: the case for observation
Beck, Stephen D. W.
Foster, Richard S.
WORLD JOURNAL OF UROLOGY, 2009, 27 (04) : 485 - 488
[3] Cohort studies in oral precancer management: Intervention vs. observation
Thomson, P. J.
Goodson, M. L.
Hamadah, O.
ORAL ONCOLOGY, 2009, : 116 - 116
[4] How valid is a prediction rule for residual retroperitoneal mass histology in NSGCT?
Vergouwe, Y
Steyerberg, EW
Habbema, JDF
GERM CELL TUMOURS V, 2002, : 165 - 165
[5] Comparing the perioperative management of postchemotherapy retroperitoneal lymph node dissection (PCRPLND) in patients with pure seminomatous and nonseminomatous germ cell tumors (NSGCT)
Pfister, D. J.
Busch, J.
Winter, C.
Schrader, M.
Dieckmann, K.
Schmelz, H. U.
Albers, P.
Heidenreich, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
[6] Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT)
Kuczyk, M
Machtens, S
Stief, C
Jonas, U
INTERNATIONAL JOURNAL OF CANCER, 1999, 83 (06) : 852 - 855
[7] Management of residual nonretroperitoneal disease in nonseminomatous germ-cell tumors (NSGCT).
King, Jennifer
Kesler, Kenneth
Ashkar, Ryan
Althouse, Sandra K.
Hanna, Nasser H.
Einhorn, Lawrence H.
Adra, Nabil
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] Analysis of covariance vs. "residual change"
Twisk, J
Proper, K
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2005, 58 (05) : 542 - 542
[9] Residual waters vs. multiresistant bacteria
Joadas, Andreia
Nicolau, Bruno
Maia e Silva, Alexandra
Barroso, Helena
Duarte, Aida
ANNALS OF MEDICINE, 2019, 51 : S91 - S91
[10] Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma
Vijayakumar, Jayanthi
Jackson, Jeffrey
Ahn, Kwang W.
Hari, Parameswaran N.
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →